Model for testing immunogenicity of peptides

• US 6,939,546 B2
• Filed: 01/26/1998
• Issued: 09/06/2005
• Est. Priority Date: 05/21/1993
• Status: Expired due to Fees

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: The United States Of America As Represented By The Secretary Of The Army
• Inventors: Sadegh-Nasseri, Scheberazade, Reid, Robert, Wolf, Marcia Kay, Nauss, Jeffrey
• Primary Examiner(s): CELSA, BENNETT M
• Application Number:
  US09/013,077
• Publication Number:
  US 20030082193A1
• Time in Patent Office: 2,780 Days
• Field of Search: 424/184.1, 424/185.1, 514/14, 514/13
• US Class Current: 424/184.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0258 Escherichia
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.

Claims

1. An immunogenic composition comprising:

a CS3 peptide, said peptide selected from CS3 consisting of the amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No;

3.

2. The immunogenic composition of claim 1, wherein said composition is immunogenic against pathogenic microorganisms and neoplasms.

3. The immunogenic composition of claim 1, wherein said composition is immunogenic against Enterotoxigenic E. coli.

4. The immunogenic composition of claim 1, wherein said composition is combined with an immunologically acceptable carrier.

5. The immunogenic composition of claim 4 wherein said immunologically acceptable carrier comprises encapsulating microspheres.

6. The immunogenic composition of claim 5, wherein said encapsulation microspheres comprise biodegradable bio-compatible poly(DL-lactide-co-glycolide) as a bulk matrix.

7. The immunogenic composition of claim 1 wherein said peptide is a synthetic peptide.

8. The immunogenic composition of claim 1, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1.

11. The immunogenic composition of claim 8, wherein when said peptide binds to the Class II receptor DR1, it inhibits the binding of HA residues 307-319.

9. An immunogenic composition comprising:

a CS3 peptide with an amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No;

3, wherein said peptide is not a whole CS3 protein.

10. The immunogenic composition of claim 9, wherein when said peptide is minimized, the minimized peptide binds to a Class II MHC receptor DR1.

12. The immunogenic composition of claim 10, wherein said peptide binds to the Class II receptor DR1, it inhibits the binding of HA residues 307-319.